To identify the level of ENO1 protein expression in AML and MDS patient tumour cells, ENO1 was examined by immunohistochemistry in bone marrow trephine samples obtained from 5 AML patients (2M, 3F; 4 with favourable and 1 with adverse 2022 ELN risk classification [24]) at diagnosis and again at morphological remission, and 12 MDS patients (8M, 4F; disease risk classification unknown) at diagnosis. The gene discussed is ENO1; the disease is neoplasm.